Literature DB >> 28059789

The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.

Zahinoor Ismail1,2, Luis Agüera-Ortiz3, Henry Brodaty4, Alicja Cieslak2, Jeffrey Cummings5, Corinne E Fischer6, Serge Gauthier7, Yonas E Geda8, Nathan Herrmann9,10, Jamila Kanji2, Krista L Lanctôt10, David S Miller11, Moyra E Mortby12, Chiadi U Onyike13, Paul B Rosenberg13, Eric E Smith2, Gwenn S Smith14, David L Sultzer15, Constantine Lyketsos16.   

Abstract

BACKGROUND: Mild behavioral impairment (MBI) is a construct that describes the emergence at ≥50 years of age of sustained and impactful neuropsychiatric symptoms (NPS), as a precursor to cognitive decline and dementia. MBI describes NPS of any severity, which are not captured by traditional psychiatric nosology, persist for at least 6 months, and occur in advance of or in concert with mild cognitive impairment. While the detection and description of MBI has been operationalized in the International Society to Advance Alzheimer's Research and Treatment - Alzheimer's Association (ISTAART-AA) research diagnostic criteria, there is no instrument that accurately reflects MBI as described.
OBJECTIVE: To develop an instrument based on ISTAART-AA MBI criteria.
METHODS: Eighteen subject matter experts participated in development using a modified Delphi process. An iterative process ensured items reflected the five MBI domains of 1) decreased motivation; 2) emotional dysregulation; 3) impulse dyscontrol; 4) social inappropriateness; and 5) abnormal perception or thought content. Instrument language was developed a priori to pertain to non-demented functionally independent older adults.
RESULTS: We present the Mild Behavioral Impairment Checklist (MBI-C), a 34-item instrument, which can easily be completed by a patient, close informant, or clinician.
CONCLUSION: The MBI-C provides the first measure specifically developed to assess the MBI construct as explicitly described in the criteria. Its utility lies in MBI case detection, and monitoring the emergence of MBI symptoms and domains over time. Studies are required to determine the prognostic value of MBI for dementia development, and for predicting different dementia subtypes.

Entities:  

Mesh:

Year:  2017        PMID: 28059789      PMCID: PMC5652315          DOI: 10.3233/JAD-160979

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  41 in total

1.  The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease.

Authors:  Paul B Rosenberg; Michelle M Mielke; Brian S Appleby; Esther S Oh; Yonas E Geda; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

2.  Neuropsychiatric symptoms as risk factors for progression from CIND to dementia: the Cache County Study.

Authors:  M E Peters; P B Rosenberg; M Steinberg; M C Norton; K A Welsh-Bohmer; K M Hayden; J Breitner; J T Tschanz; C G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

3.  The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia.

Authors:  Kate de Medeiros; P Robert; S Gauthier; F Stella; A Politis; J Leoutsakos; F Taragano; J Kremer; A Brugnolo; A P Porsteinsson; Y E Geda; H Brodaty; G Gazdag; J Cummings; C Lyketsos
Journal:  Int Psychogeriatr       Date:  2010-07-01       Impact factor: 3.878

Review 4.  Cholinesterase-inhibitor Associated Mania: A Case Report and Literature Review.

Authors:  Hamza Jalal; Aravind Ganesh; Raymond Lau; John Lysack; Zahinoor Ismail
Journal:  Can J Neurol Sci       Date:  2014-03       Impact factor: 2.104

5.  Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer's disease.

Authors:  Kristiina Karttunen; Pertti Karppi; Asta Hiltunen; Matti Vanhanen; Tarja Välimäki; Janne Martikainen; Hannu Valtonen; Juhani Sivenius; Hilkka Soininen; Sirpa Hartikainen; Jaana Suhonen; Tuula Pirttilä
Journal:  Int J Geriatr Psychiatry       Date:  2010-10-29       Impact factor: 3.485

Review 6.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  Behavioral symptoms in mild cognitive impairment.

Authors:  H Feldman; P Scheltens; E Scarpini; N Hermann; P Mesenbrink; L Mancione; S Tekin; R Lane; S Ferris
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

8.  The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.

Authors:  J L Cummings; M Mega; K Gray; S Rosenberg-Thompson; D A Carusi; J Gornbein
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

9.  Cognitive decline and dementia risk in older adults with psychotic symptoms: a prospective cohort study.

Authors:  Sebastian Köhler; Judith Allardyce; Frans R J Verhey; Ian G McKeith; Fiona Matthews; Carol Brayne; George M Savva
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-22       Impact factor: 4.105

10.  The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline.

Authors:  Sarah Jane Banks; Rema Raman; Feng He; David P Salmon; Steven Ferris; Paul Aisen; Jeffrey Cummings
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-12-18
View more
  75 in total

Review 1.  A practical approach to detection and treatment of depression in Parkinson disease and dementia.

Authors:  Zahra Goodarzi; Zahinoor Ismail
Journal:  Neurol Clin Pract       Date:  2017-04

2.  EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.

Authors:  P Aisen; J Touchon; R Amariglio; S Andrieu; R Bateman; J Breitner; M Donohue; B Dunn; R Doody; N Fox; S Gauthier; M Grundman; S Hendrix; C Ho; M Isaac; R Raman; P Rosenberg; R Schindler; L Schneider; R Sperling; P Tariot; K Welsh-Bohmer; M Weiner; B Vellas
Journal:  J Prev Alzheimers Dis       Date:  2017

3.  Trajectories of neuropsychiatric symptoms over time in healthy volunteers and risk of MCI and dementia.

Authors:  Jeannie-Marie S Leoutsakos; Elizabeth A Wise; Constantine G Lyketsos; Gwenn S Smith
Journal:  Int J Geriatr Psychiatry       Date:  2019-09-02       Impact factor: 3.485

4.  Association of TDP-43 Pathology With Domain-specific Literacy in Older Persons.

Authors:  Alifiya Kapasi; Lei Yu; Christopher C Stewart; Julie A Schneider; David A Bennett; Patricia A Boyle
Journal:  Alzheimer Dis Assoc Disord       Date:  2019 Oct-Dec       Impact factor: 2.703

Review 5.  Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications.

Authors:  Rita Khoury; George T Grossberg
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

6.  Prevalence of mild behavioral impairment in patients with mild cognitive impairment.

Authors:  Gilda Kianimehr; Farzad Fatehi; Maryam Noroozian
Journal:  Acta Neurol Belg       Date:  2021-06-30       Impact factor: 2.396

7.  Affective Neuropsychiatric Symptoms as Early Signs of Dementia Risk in Older Adults.

Authors:  Jung Yun Jang; Jean K Ho; Anna E Blanken; Shubir Dutt; Daniel A Nation
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

8.  The Effect of Personality Traits on Risk of Incident Pre-dementia Syndromes.

Authors:  Emmeline Ayers; Emma Gulley; Joe Verghese
Journal:  J Am Geriatr Soc       Date:  2020-06-02       Impact factor: 5.562

Review 9.  Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia? Review of Key Points Toward an Accurate Clinical and Neuropsychological Diagnosis.

Authors:  Gada Musa; Andrea Slachevsky; Carlos Muñoz-Neira; Carolina Méndez-Orellana; Roque Villagra; Christian González-Billault; Agustín Ibáñez; Michael Hornberger; Patricia Lillo
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  Apathy in Preclinical Alzheimer's Disease: Psychometric Validation of the Apathy Evaluation Scale.

Authors:  Emre Umucu; Mary Wyman; Beatrice Lee; Megan Zuelsdorff; Susan Flowers Benton; Naomi Nystrom; Sterling C Johnson; Cynthia M Carlsson; Sanjay Asthana; Carey E Gleason
Journal:  Am J Alzheimers Dis Other Demen       Date:  2018-08-14       Impact factor: 2.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.